Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;14:1455–1468. doi: 10.2147/DDDT.S243420

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Liao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Isoliquiritigenin relieved fibrosis in vivo and in vitro by inhibiting Mincle. (A–D). According to the results of Western blot and Immunohistochemistry, ISL significantly inhibited the protein level of fibrosis markers α-SMA, Col III and FN in the kidney of UUO mice. **P<0.01, vs UUO group. ***P<0.001, vs UUO group; (E) Masson staining also showed a significant decrease in fiber deposition after ISL treatment; (F–H) after treating with TDB, reduction of α-SMA and FN by ISL in TGF-β-stimulated BMDM was significantly upregulated, suggesting the key role of Mincle in inhibition of fibrosis by ISL.

Notes: *P<0.05, vs TGF-β group. **P<0.01, vs TGF-β group. #P<0.05, vs TGF-β+ISL 40 μM-treated group. ##P<0.01, vs TGF-β+ISL 40 μM-treated group.